Safety and immunogenicity of a parenteral trivalent P2-VP8 subunit rotavirus vaccine

Michelle J. Groome1,2, Lee Fairlie3, Julie Morrison4, Alan Fix5, Anthonet Koen1,2, Maysseb Masenya3, Lisa Jose3,2, Shabir A. Madhi1,2, Nicola Page6,7, Monica McNeal8, Len Dally3, Iksung Cho5, Maureen Power5, Jorge Flores5, Stanley Cryz2

1Medical Research Council: Respiratory and Meningeal Pathogens Research Unit, University of the Witwatersrand, South Africa; 2Department of Science and Technology/National Research Foundation: Vaccine Preventable Diseases, University of the Witwatersrand, South Africa; 3Wits Reproductive Health and HIV Institute, University of the Witwatersrand, South Africa; 4Family Clinical Research Unit, Stellenbosch University, South Africa; 5PATH, Seattle, WA, USA; 6National Institute for Communicable Diseases: a division of National Health Laboratory Service, South Africa; 7Department of Medical Virology, Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa; 8Division of Infectious Diseases, Cincinnati Children’s Hospital Medical Center, Cincinnati, USA; 9The Emes Corporation, Rockville, USA.

Background and aims
A P[8] monovalent parenteral subunit rotavirus vaccine (P2-VP8-P[8]) was well-tolerated and immunogenic, but elicited limited responses against heterotypic rotavirus strains. We expanded valency to include the three most common P types and evaluated safety and immunogenicity of this trivalent formulation (P2-VP8-P[4],[6],[8]) in South African adults, toddlers and infants.

Methods
A multi-site, double-blind, randomised, placebo-controlled trial was conducted from February 2016–December 2017. Two dose-levels were assessed in healthy adults and toddlers; thereafter three dose-levels were assessed in term infants ≥6 and <8 weeks (three injections four weeks apart). Primary safety endpoints included local and systemic reactions within seven days and adverse events within 28 days after each injection. Primary immunogenicity endpoints, among infants receiving all study injections per protocol, compared serum anti-P2-VP8 IgA and IgG, and neutralising antibody responses in sera four weeks after the final injection, in each vaccine group to placebo. Rotarix® was administered after completion of study vaccinations, and its faecal shedding was assessed by ELISA in a subset of infants.

Results
Thirty adults, 30 toddlers and 557 infants were assessed for safety, with no significant differences observed between vaccine/placebo groups in the proportions with local reactions, systemic reactions or adverse events. The proportions of infants with anti-P2-VP8 IgG seroresponses to all three antigens (P[4], P[6] and P[8]) were significantly higher in the 15µg, 30µg and 90µg groups (99, 99 and 100%, respectively) compared to placebo (9%; p<0.0001). Although significantly higher than in placebo recipients, the proportions of infants with anti-P2-VP8 IgA seroresponses to each individual antigen were modest (20–34%) across all three active dose groups. The proportions of infants with neutralizing antibody seroresponses to rotaviruses representing all three types (P[4], P[6] and P[8]) in the vaccine were 8, 50, 61 and 62%, respectively, in the placebo, 15µg, 30µg and 90µg groups: significantly higher than placebo recipients (p<0.0001). There was a 41% reduction in PCR-confirmed Rotarix shedding in the 90µg group compared to placebo (95% CI: 0.1–65, p=0.0346).

Conclusion
The trivalent P2-VP8 vaccine was well-tolerated, with promising anti-P2-VP8 IgG and neutralising antibody responses across the three vaccine P-types.